Novo Nordisk has received accelerated approval for Wegovy, the first GLP-1 therapy for metabolic dysfunction-associated steatohepatitis (MASH).
Raluca Ioana Draghici
International
www.shutterstock.com
Always see our news on Google
The FDA has fast-tracked approval of Novo Nordisk's drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), affecting 5% of US adults. This is the first GLP-1 class therapy approved for MASH aimed at improving liver function. Preliminary studies have shown promising results, and Novo Nordisk has already applied for approval in Europe and Japan, expecting final trial results in 2029.
Sources
Latest News
23:00
NASA has published images of the crater formed on the Moon after the Falcon 9 rocket stage crashed on August 5.
22:53
ECB: Europe cannot afford to miss the opportunities offered by artificial intelligence
22:49
Energy consumption is on the rise. When is the peak consumption expected this year?
22:45
The assessment of the buildings affected by the explosion in Rahova has begun. The operation will conclude on September 9.
22:35
Bogdan Ivan responds to Ilie Bolojan, asking him to confirm that large energy consumers will not be affected by power cuts.
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
